Mutational analysis of the p16 gene in human neuroblastomas

Molecular Carcinogenesis

Volumn 18, Issue 3, 1997, Pages 129-133

  Castresana, Javier S ^a,b   Gómez, Lourdes ^b   García Miguel, Purificación ^b   Queizán, Antonio ^b   Pestaña, Angel ^a  

^a CSIC   (Spain)

^b HOSPITAL INFANTIL LA PAZ   (Spain)

Author keywords

Cancer; CDKN2; MTS1; Polymerase chain reaction; Single strand conformation polymorphism; Tumor suppressor gene

Indexed keywords

ARTICLE; GANGLIONEUROMA; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTASIS; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; EXONS; GANGLIONEUROMA; GENES, TUMOR SUPPRESSOR; HUMANS; INFANT; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RESTRICTION MAPPING; SEQUENCE DELETION;

EID: 1842339876     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199703)18:3<129::AID-MC1>3.0.CO;2-A     Document Type: Article

References (34)

1. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124, 1984.
2. Tanaka T, Slamon DJ, Shimoda H, et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 48:1030-1034, 1988.
3. Matsunaga T, Takahashi H, Ohnuma N, et al. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. Cancer Res 51:3148-3152, 1991.
4. Christiansen H, Christiansen NM, Wagner F, Altmannsberger M, Lampert F. Neuroblastoma: Inverse relationship between expression of N-myc and NGF-r. Oncogene 5:437-440, 1990.
5. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52:1364-1368, 1992.
6. Castresana JS, Bello MJ, Rey JA, et al. No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chromosomes Cancer 10:136-139, 1994.
7. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
8. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:22-26, 1994.
9. Kamb A, Gruis NA, Weaber-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994.
10. Nobori T, Miura K, Wu DJ, Lois A, Takabashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994.
11. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-416, 1994.
12. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (multiple suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3398, 1994.
13. Spruck CH III, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumors. Nature 370:183-184, 1994.
14. Rey JA, Bello MJ, Jimenez-Lara AM, et al. Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer 51:703-706, 1992.
15. Ueki K, Rubio M-P, Ramesh V, et al. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3:1841-1845, 1994.
16. Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153, 1996.
17. Castresana JS, Rubio M-P, Gómez L, Kreicbergs A, Zetterberg A, Barrios C. Detection of TP53 gene mutations in human sarcomas. Eur J Cancer 31A:735-738, 1995.
18. Castresana JS, Rubio M-P, Vázquez JJ, et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55:562-565, 1993.
19. Schneider J, Rubio M-P, Rodríguez-Escudero FJ, Seizinger BR, Castresana JS. Identification of p53 mutations by means of single strand conformation polymorphism in gynaecological tumors: Comparison with the results of immunohistochemistry. Eur J Cancer 30A:504-508, 1994.
20. Schneider J, Rubio M-P, Barbazán MJ, Rodríguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 86:850-855, 1994.
21. Zhang S-Y, Klein-Szanto AJP, Sauter ER, et al. Higher freguency of alterations in the p16/CDKN2 gene in sguamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994.
22. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16 in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994.
23. Zhou X, Tarmin L, Jiang HY, et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9:3737-3741, 1994.
24. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55:20-23, 1995.
25. Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55:514-517, 1995.
26. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551, 1994.
27. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353-6358, 1994.
28. INK4 expression is frequent in high grade gliomas. Cancer Res 55:1941-1945, 1995.
29. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493-497, 1995.
30. Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54:6078-6082, 1994.
31. INK4 Cancer Res 54:5816-5820, 1994.
32. INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995.
33. Beltinger CP, White PS, Sulman EP, Maris JM, Brodeur GM. No CDKN2 mutations in neuroblastomas. Cancer Res 55:2053-2055, 1995.
34. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535, 1995.